In the present study, three methods for determination of hormone receptor status were applied in relation to RFi and OS in premenopausal breast cancer patients treated with tamoxifen in comparison to a control group in a randomised trial with long-term follow-up. Here, NR4A1 is linked to breast carcinoma.